Avanos Medical announced today that a Centers for Medicare and Medicaid Services (CMS) payment rule benefits its infusion systems. CMS issued its final Medicare Hospital Outpatient Prospective Payment System (OPPS) and Medicare Ambulatory Surgical Center (ASC) Payment System rule for 2025. The rule goes into effect on Jan. 1, 2025, implementing the Non-Opioids Prevent Addiction […]
avanosmedical
Avanos rises as Q1 earnings match Wall Street projections
Avanos Medical (NYSE:AVNS) shares ticked up today on first-quarter results that just about matched the consensus forecast. The Alpharetta, Georgia–based pain management and chronic care device company posted profits of $5.8 million, or 12¢ per share, on sales of $197.4 million for the three months ended March 31, 2022, for a bottom-line gain from losses of […]
Avanos Medical to buy OrthogenRx for $160M
Avanos Medical today announced it entered into a definitive agreement to acquire OrthogenRx for $160 million. OrthogenRx makes viscosupplementation therapies to treat knee osteoarthritis pain, as well as commercial hyaluronic acid (HA) therapy products GenVisc 850 and TriVisc. Avanos will purchase the company for $130 million in cash at closing and an additional $30 million […]
Avanos Medical wins FDA nod for ON-Q Bolus pump
Avanos Medical (NYSE: AVNS), which rebranded from Halyard Health last June, said today that it won FDA 510(k) clearance for its ON-Q* with Bolus pump drug infusion device. The Alpharetta, Ga.-based company said that the new ON-Q* with Bolus system features improvements to improve ease of use and reduce postoperative opioid use for pain management. The newly cleared device […]
